CoChat
Sign Up
Cited by 151Wnt/β-catenin signaling in development and cancerProstate Cancer Treatment and ResearchSignaling Pathways in Disease

The DOI matches its Crossref record; 92 of the 93 references it cites were found in a registry or an index.

Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor

Chesire, Dennis R, Isaacs, William B·2002·Oncogene
DOI 10.1038/sj.onc.1206049
Open this paper in CoChat — free account

Abstract

Beta-catenin signaling may contribute to prostate cancer (CaP) progression. Although beta-catenin is known to upregulate T cell factor (TCF) target gene expression in CaP cells, recent evidence demonstrates its capacity to enhance ligand-dependent androgen receptor (AR) function. Thus, we wished to further understand the interaction between these two pathways. We find in both CaP cells (CWR22-Rv1, LAPC-4, DU145) and non-CaP cells (HEK-293, TSU, SW480, HCT-116) that beta-catenin/TCF-related transcription (CRT), as measured by activation of a synthetic promoter and that of cyclin D1, is inhibited by androgen treatment. This inhibition is AR-dependent, as it only occurs in cells expressing AR endogenously or transiently, and is abrogated by AR antagonists. Additional analyses convey that the ligand-dependent nature of CRT suppression depends on transactivation-competent AR in the nucleus, but not on indirect effects stemming from AR target gene expression. Given the recent work identifying an AR/beta-catenin interaction, and from our finding that liganded AR does not prompt gross changes in the constitutive nuclear localization of TCF4 or mutant beta-catenin, we hypothesized that transcription factor (i.e. AR and TCF) competition for beta-catenin recruitment may explain, in part, androgen-induced suppression of CRT. To address this idea, we expressed an AR mutant lacking its DNA-binding domain (DBD). This receptor could not orchestrate ligand-dependent CRT repression, thereby providing support for those recent data implicating the AR DBD/LBD as necessary for beta-catenin interaction. Further supporting this hypothesis, TCF/LEF over-expression counteracts androgen-induced suppression of CRT, and requires beta-catenin binding activity to do so. Interestingly, TCF4 over-expression potently antagonizes AR function; however, this inhibition may occur independently of beta-catenin/TCF4 interaction. These results from TCF4 over-expression analyses, taken together, provide further evidence that AR-mediated suppression of CRT is a consequence of limiting amounts of beta-catenin, and not AR target gene expression. Our analyses point to a reciprocal balance between AR and CRT function that may shape critical processes during normal prostate development and tumor progression.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1206049

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 93 references

Research works printed but not linked: 2

  1. Hovanes K, Li TW, Munguia JE, Truong T, Milovanovic T, Lawrence MJ, Holcombe RF, Waterman ML . 2001 Nat. Genet. 28: 53–57 · DOI
  2. Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, Stallcup MR, Press MF, Coetzee GA . 2000 Cancer Res. 60: 5946–5949

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Chesire, D. R., & Isaacs, W. B.
Affiliations
Johns Hopkins University (US)
Corresponding author
Isaacs, William B
ORCID
Isaacs, William B
Venue
Oncogene
Publisher
Springer Science and Business Media LLC
Published
2002-12-04
Volume
21
Issue
55
Pages
8453-8469
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
DOI
10.1038/sj.onc.1206049
OpenAlex
W1970833195
Cited by
151
References
93
Citations by year
2026: 3 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 8 · 2020: 4 · 2019: 7 · 2018: 2 · 2017: 9 · 2016: 5 · 2015: 5 · 2014: 8 · 2013: 9 · 2012: 10
FWCI
3.36
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Cancer Institute (CA58236, P50CA058236)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords
androgen receptor, β-catenin, TCF/LEF, Wnt signaling, prostate cancer, ligand-dependent transcription, transcription factor competition, TCF4, cyclin D1, DNA-binding domain, transcriptional repression
MeSH terms
Animals, Cell Line, Cell Nucleus, Cytoskeletal Proteins, DNA-Binding Proteins, Humans, Ligands, Male, Prostatic Neoplasms, Receptors, Androgen, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Signal Transduction, Trans-Activators, beta Catenin, TCF Transcription Factors, Transcription Factor 7-Like 2 Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review